Osimertinib is currently the preferred first-line therapy in patients with NSCLC with common EGFR mutation and the standard second-line therapy in T790M-positive patients in progression to previous EGFR-TKIs (47, 48). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.